Browse > Article

Effects of Nalbuphine on the Primary Humoral Immune Response in Mice  

Yun, Hee-Eun (College of Pharmacy, Sookmyung Women's University)
Pyo, Myoung-Yun (College of Pharmacy, Sookmyung Women's University)
Publication Information
Environmental Analysis Health and Toxicology / v.20, no.4, 2005 , pp. 343-350 More about this Journal
Abstract
In order to investigate the of effects of nalbuphine on immune system in mice, we examined the various immunological parameters. After single oral administration of nalbuphine (130, 260, 390 mg/kg, i.p.) to female ICR mite, the weights of bodies and organs (thymus, spleen, liver, kidney), and hematological parameters were examined on day 2, 4, 6, and 8. The increased rate of body weight, relative weight of organ, and hematological parameters in nalbuphine -treated groups, were not significantly changed when compared with control group. However, number of WBC was decreased by the treatment of nalbuphine. To assess the effects of nalbuphine on humoral immune responses, splenic IgM plaque forming cell (PFC) and serum IgM were assayed. When nalbuphine wat administered after immunization with SRBC, but not before immunization, splenic IgM PFC and ,serum IgM level against SRBC were significantly lowered in a dole -dependent manner. These results indicate that the suppressive effects of nalbuphine on primary humoral immune response may be dependent on the timing of its administration relative to the initial antigenic sensitization.
Keywords
nalbuphine; lgM PFC; serum IgM;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Loren DK. Decreased antibody formation in mice exposed to lead, Nature 1974; 250: 148-250   DOI   PUBMED   ScienceOn
2 Mischell BB and Shiigi SM. Selected methods in cellular immunology, WH Freman and Company, San Francisco, U.S.A .. 1980, pp. 16-17
3 Stambaugh JE. Evaluation of nalbuphine; Efficacy and Safety in the Management of Chronic Pain Associated With Advanced Malignancy, Current Therapeutic Research. 1982; 31(3): 393-401
4 Yoo YC, Chung HS and Kim IS. Determination of Nalbuphine in Drug Abuser' Urine, J of Analytical Toxicology 1995; 19: 120-123   DOI
5 Kaminski NE. Mechanism of immune modulation by cannabinoids, in Dean JH, Luster MI, Munson AE, Kimber I (eds): Immunotoxicology and Immunopharmacology, 2d ed. New York: Raven Press, 1994, pp. 349-362
6 Cada DJ, Covington T, Hebel SK, Hussar DA, Lasagna L and Olin BR. Drug facts and comparisons, 1999 Edition, Facts and Comparisons 1999, pp 1433-1434
7 Lo MW, Schary WL and Whitney CC. The disposition and bioavailability of intravenous and oral nalbuphine in healthy volunteers, J Clin Pharmaco 1983; 27: 866-873
8 Reynolds EF. In Martindale The Extra Phamacopoeia, 13th ed., Pharmaceutical Press, London, England, 1993, pp. 1090
9 Smialowicz RJ and Holsapple MP. Experimental Immuno-toxicology Boca Raton, FL, CRC Press, 1996, pp. 13-15
10 McBride AJ. Three cases of nalbuphine hydrochloride dependence associated with anabolic steroid use, Br J Sports Med 1996; 30: 69-70   DOI   ScienceOn
11 Chung HS. Pharmacokinetics of nalbuphine in overdosage as a psychotropic agent, Annual Report of N.I.S.I., 2002; 34: 149-154
12 LeVier DG, McCay JA and Stern ML. Immunotoxicological profile of morphine sulfate in B6C3F1 mice, Fundam Appl Toxicol 1994; 22: 525-542   DOI   ScienceOn
13 Litchfield JT and Wilcoxon F. A simplified Method of Evaluating Dose-effect Experiments, J Pharmacol Exp Ther 1943; 96: 99-113
14 Matveyeva M, Hartman CB and Harrison MT. Delta(9)-tetrahydrocannabinol selectively increases aspartyl cathepsin D proteolytic activity and impairs lysozomal processing in macrophages, Int J Immunopharmacol 2000; 22(5): 373-381   DOI   ScienceOn
15 Cunnigham A and Szenberg A. Futher improvements in plaque technique for detecting single antibody-forming cells, Immunol 1968; 14: 599-600